Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Dec;57(12):6147-53.
doi: 10.1128/AAC.01285-13. Epub 2013 Sep 30.

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults

Gabriel J Robbie  1 , Ryan Criste, William F Dall'acqua, Kathryn Jensen, Nita K Patel, Genevieve A Losonsky, M Pamela Griffin
Affiliations
Clinical Trial

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults

Gabriel J Robbie et al. Antimicrob Agents Chemother. 2013 Dec.

Abstract

The study objective was to evaluate the pharmacokinetics (PK), antidrug antibody (ADA), and safety of motavizumab-YTE (motavizumab with amino acid substitutions M252Y/S254T/T256E [YTE]), an Fc-modified anti-respiratory syncytial virus (RSV) monoclonal antibody. Healthy adults (n = 31) were randomized to receive a single intravenous (i.v.) dose of motavizumab-YTE or motavizumab (0.3, 3, 15, or 30 mg/kg) and followed for 240 days. Clearance of motavizumab-YTE was significantly lower (71% to 86%) and the half-life (t1/2) was 2- to 4-fold longer than with motavizumab. However, similar peak concentrations and volume-of-distribution values, indicative of similar distribution properties, were seen at all dose levels. The sustained serum concentrations of motavizumab-YTE were fully functional, as shown by RSV neutralizing activity that persisted for 240 days with motavizumab-YTE versus 90 days postdose for motavizumab. Safety and incidence of ADA were comparable between groups. In this first study of an Fc-modified monoclonal antibody in humans, motavizumab-YTE was well tolerated and exhibited an extended half-life of up to 100 days. (This study has been registered at ClinicalTrials.gov under registration no. NCT00578682.).

PubMed Disclaimer

Figures

Fig 1
Fig 1
Disposition of subjects in the four treatment cohorts.
Fig 2
Fig 2
Dose proportionality of mota-YTE and motavizumab maximum concentration and area under the curve.
Fig 3
Fig 3
Means (± standard deviations) of mota-YTE and motavizumab serum concentrations after a single dose. d, days.
Fig 4
Fig 4
(A) Predose baseline anti-RSV neutralizing antibody titers. (B) Postdose anti-RSV neutralizing activity of mota-YTE and motavizumab. EC50, half-maximal effective concentration. aSpiked concentrations were derived by protein quantification normalized to dilution.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360:588–598 - PMC - PubMed
    1. American Academy of Pediatrics 2012. Respiratory syncytial virus, p 609–617 In Pickering LK, Baker CJ, Kimberlin DW, Long SS. (ed), Red book: 2012 report of the Committee on Infectious Diseases, 29th ed. American Academy of Pediatrics, Elk Grove Village, IL
    1. Mould DR, Sweeney KR. 2007. The pharmacokinetics and pharmacodynamics of monoclonal antibodies—mechanistic modeling applied to drug development. Curr. Opin. Drug Discov. Devel. 10:84–96 - PubMed
    1. Roopenian DC, Akilesh S. 2007. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7:715–725 - PubMed
    1. Simister NE, Mostov KE. 1989. An Fc receptor structurally related to MHC class I antigens. Nature 337:184–187 - PubMed

Publication types

Associated data